Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

CE-355621

Copy Product Info
🥰Excellent

Synonyms:

Catalog No. T9901A-1782 Copy Product Info
🥰Excellent
CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. It effectively binds to human c-Met in A549 cells (KD= 200 pM, IC50= 466 pM) and also binds effectively to c-Met in cynomolgus monkey kidney cells (KD= 610 pM). CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding and significantly suppresses tumor growth dependent on the c-Met/HGF pathway. It is applicable for research in cancers such as glioblastoma and gastric cancer.

CE-355621

Pack SizePriceUSA StockGlobal StockQuantity
1 mgInquiryInquiryInquiry
5 mgInquiryInquiryInquiry
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Product Introduction

Bioactivity
Description
CE-355621 is a humanized anti-c-Met IgG1 monoclonal antibody. It effectively binds to human c-Met in A549 cells (KD= 200 pM, IC50= 466 pM) and also binds effectively to c-Met in cynomolgus monkey kidney cells (KD= 610 pM). CE-355621 inhibits the c-Met signaling pathway by blocking HGF binding and significantly suppresses tumor growth dependent on the c-Met/HGF pathway. It is applicable for research in cancers such as glioblastoma and gastric cancer.
In vitro
CE-355621 is effective in blocking the binding of c-Met with HGF and induces c-Met degradation in A549 cells at concentrations ranging from 0.01 to 100 nM over 4 hours. At concentrations of 0.01 nM to 10 nM for 24 hours, CE-355621 significantly inhibits c-Met activation in U87MG cells. Additionally, it induces c-Met degradation in U87MG cells at concentrations of 0.01 to 10 μg/mL over a 48-hour period.
In vivo
Administered intraperitoneally, CE-355621 at doses ranging from 25-200 μg on days 0, 2, 3, 6, and 8 significantly delayed tumor growth in U87MG xenografts in female CD-1 nu/nu mice. Additionally, a dose of 400 μg on days 7 and 14 markedly inhibited tumor growth of GTL-16 xenografts in the same mouse model. A single dose of 200 μg on day 7 effectively reduced tumor volume growth and [18 F-FDG] uptake in U87MG xenografts in female nude mice (nu/nu).
Storage & Solubility Information
StorageStore at low temperature Store at -20°C Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: CE-355621 in vivo | CE-355621 in vitro